Galvanize Therapeutics's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·59 fund marks: filer, period, implied $/share
Membership and data by Private Market View
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Galvanize Therapeutics funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jul 2025 | Later Stage VC (Series C) | $100.0M | ▮ | ▮ |
| Mar 2022 | Later Stage VC (Series B) | $100.0M | ▮ | ▮ |
| Feb 2022 | Debt | $2.0M | ▮ | ▮ |
| Mar 2020 | Early Stage VC | $6.1M | ▮ | ▮ |
Membership and data by Private Market View
Galvanize Therapeutics valuation
Galvanize Therapeutics's last reported valuation was $300 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
Recent activity
In the last 90 days, Galvanize Therapeutics's record added 3 institutional fund marks (latest period Jul 2026).
How much has Galvanize Therapeutics raised?
Galvanize Therapeutics has raised $206 million across 4 recorded rounds since 2020. The largest was a $6.1 million early-stage round in Mar 2020; the most recent was a $100 million Series C in Jul 2025.
Galvanize Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently in Sep 2025 ($96.1 million sold to 28 investors).
Institutional holders and vehicles
3 SEC-registered funds reported 59 fair-value marks on Galvanize Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Comparable companies
Comparable therapeutic devices names by valuation on PrivateMarketView: Saluda Medical ($435 million), LightForce ($400 million) and Soufflé Therapeutics ($345 million).
How Galvanize Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Galvanize Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Galvanize Therapeutics
- What is Galvanize Therapeutics worth?
- Galvanize Therapeutics is valued at $300.0M as of Oct 2026. Galvanize Therapeutics's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- How much has Galvanize Therapeutics raised?
- Galvanize Therapeutics has raised $206.1M in total funding across 4 recorded rounds.
- When did Galvanize Therapeutics last raise?
- Galvanize Therapeutics last raised in Jul 2025 (Later Stage VC (Series C)), raising $100.0M.